These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 12771636

  • 21. Antifungal resistance: the clinical front.
    Perfect JR.
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
    [Abstract] [Full Text] [Related]

  • 22. Caspofungin in the treatment of oropharyngeal candidiasis.
    Garbino J, Lew D, Hirschel B, Rohner P.
    Int J Clin Pract; 2003 Mar; 57(2):143-4. PubMed ID: 12661800
    [Abstract] [Full Text] [Related]

  • 23. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
    Hakki M, Staab JF, Marr KA.
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
    Lichtenstern C, Nguyen TH, Schemmer P, Hoppe-Tichy T, Weigand MA.
    Mycoses; 2008 Jul; 51 Suppl 1():35-46. PubMed ID: 18471160
    [Abstract] [Full Text] [Related]

  • 25. Breakthrough Candida dubliniensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin.
    Fanci R.
    J Chemother; 2009 Feb; 21(1):105-7. PubMed ID: 19297283
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
    Kabbara N, Lacroix C, Peffault de Latour R, Socié G, Ghannoum M, Ribaud P.
    Haematologica; 2008 Apr; 93(4):639-40. PubMed ID: 18379015
    [No Abstract] [Full Text] [Related]

  • 28. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
    Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM.
    Clin Infect Dis; 2009 Jun 15; 48(12):1695-703. PubMed ID: 19441981
    [Abstract] [Full Text] [Related]

  • 29. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B.
    Sorà F, Chiusolo P, Piccirillo N, Pagano L, Laurenti L, Farina G, Sica S, Leone G.
    Clin Infect Dis; 2002 Nov 01; 35(9):1135-6. PubMed ID: 12384850
    [No Abstract] [Full Text] [Related]

  • 30. Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.
    Conen A, Weisser M, Jörg CO, Battegay M, Trampuz A, Frei R, Christen S, Heim D, Gratwohl A, Flückiger U.
    Transpl Infect Dis; 2008 Feb 01; 10(1):66-70. PubMed ID: 17511816
    [Abstract] [Full Text] [Related]

  • 31. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J.
    Bone Marrow Transplant; 2001 Nov 01; 28(9):873-8. PubMed ID: 11781648
    [Abstract] [Full Text] [Related]

  • 32. [Three cases of fungemia caused by Blastoschizomyces capitatus].
    Koç AN, Copur Çiçek A, Kaynar L, Sav H, Kasap Tekinşen FF, Atalay MA.
    Mikrobiyol Bul; 2013 Oct 01; 47(4):734-41. PubMed ID: 24237444
    [Abstract] [Full Text] [Related]

  • 33. Caspofungin in kidney transplant recipients with refractory invasive candidiasis.
    Veroux M, Corona D, Macarone M, Gagliano M, Giuffida G, Veroux P.
    Nephrol Dial Transplant; 2007 May 01; 22(5):1487-9. PubMed ID: 17210588
    [No Abstract] [Full Text] [Related]

  • 34. Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns.
    Pemán J, Jarque I, Bosch M, Cantón E, Salavert M, de Llanos R, Molina A.
    J Clin Microbiol; 2006 May 01; 44(5):1912-4. PubMed ID: 16672439
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia.
    Hübel K, Chemnitz J, Brochhagen HG, Cornely OA.
    Int J Hematol; 2004 Apr 01; 79(3):289-92. PubMed ID: 15168600
    [Abstract] [Full Text] [Related]

  • 37. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.
    Cohen Y, Karoubi P, Adrie C, Gauzit R, Marsepoil T, Zarka D, Clec'h C.
    Crit Care Med; 2010 Mar 01; 38(3):826-30. PubMed ID: 20042858
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
    Bannatyne RM, Cheng PC, Fong IW.
    Infection; 1992 Mar 01; 20(3):168-70. PubMed ID: 1644494
    [Abstract] [Full Text] [Related]

  • 39. Caspofungin therapy of neonates with invasive candidiasis.
    Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfaro B, Sàenz A, Herrera ML, Walsh TJ.
    Pediatr Infect Dis J; 2004 Dec 01; 23(12):1093-7. PubMed ID: 15626944
    [Abstract] [Full Text] [Related]

  • 40. Caspofungin versus amphotericin B for the treatment of Candidal esophagitis.
    Chocarro Martínez A, Gonzalez A, Garcia I.
    Clin Infect Dis; 2002 Jul 01; 35(1):107; author reply 107-8. PubMed ID: 12060888
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.